Abstract Library

#1168 Simultaneous Large Cell Neuroendocrine Carcinoma and Adenocarcinoma of the Stomach: A Case Report and Literature Review

Introduction: Large cell neuroendocrine carcinoma (LCNEC) of the stomach is rare. Gastric NEC occasionally has another component, such as adenocarcinoma, in the same tumor. However, the concurrent occurrence of LCNEC and adenocarcinoma at different sites in the stomach is extremely rare.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Nakazuru S, Matsumura Y, Harada Y, Iwasaki R, Iwasaki T,

Keywords: stomach, large cell neuroendocrine carcinoma, tubular adenocarcinoma, simultaneous,

#939 Large Cell Neuroendocrine Carcinoma of the Gallbladder: A Case Report and Literature Review

Introduction: Primary large cell neuroendocrine carcinoma (LCNEC) of the gallbladder is rare. The standard treatment for gallbladder NEC with liver metastases has not been established, but combination chemotherapy with etoposide plus cisplatin (EP) is recommended for NEC patients with liver metastasis, regardless of the primary tumor site.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Nakazuru S, Kimura K, Tada Y, Iwasaki R, Iwasaki T,

Keywords: gallbladder, large cell neuroendocrine carcinoma, chemotherapy,

#647 Reducing the Risk of Tuberculosis Reactivation when Administering Everolimus for a Pancreatic Neuroendocrine Tumor: A Case Report

Introduction: Everolimus can potentially reactivate tuberculosis (TB) through immunosuppression. This was recently reported to have occurred in a kidney transplant recipient. To date, no clear strategy has been developed for reducing the risk of TB reactivation during everolimus treatment.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Tamura T, Nakazuru S, Sakane S, Iwasaki R, Iwasaki T,

Keywords: everolimus, NET, LTBI,

#597 Primary Hepatic Neuroendocrine Carcinomas Treated with a Combination of Cisplatin and Etoposide as First-Line Chemotherapy: Two Case Reports

Introduction: Because primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare, a standard regimen has not yet been established. However, the combination of etoposide and cisplatin (EP) has been widely used to treat PHNEC.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Nakazuru S, Iwasaki R, Tamura T, Iwasaki T, Hasegawa H,

Keywords: liver, neuroendocrine carcinoma, chemotherapy,